Merck KGAA Returns PKU Drugs To BioMarin To Focus On Cancer
This article was originally published in The Pink Sheet Daily
Merck' cancer pipeline includes a potential first-in-class bi-functional immunotherapy; BioMarin anticipates taking back Kuvan commercial activities in the next 6-12 months and initiating talks with regulators over Peg-Pal's path forward.
You may also be interested in...
With the launch of Ibrance and a burgeoning immuno-oncology program, Pfizer’s oncology business is on track to generate substantial revenue and investors are starting to take note. Oncology President Liz Barrett and Chief Medical Officer Mace Rothenberg discuss Pfizer’s initiative to become a leader in the field.
Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.
Novo Nordisk and Evotec will identify and develop novel drugs for treating chronic kidney disease, using datasets of CKD patients provided by the Danish group and from other sources.